ATE411038T1 - S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung - Google Patents
S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlungInfo
- Publication number
- ATE411038T1 ATE411038T1 AT04723142T AT04723142T ATE411038T1 AT E411038 T1 ATE411038 T1 AT E411038T1 AT 04723142 T AT04723142 T AT 04723142T AT 04723142 T AT04723142 T AT 04723142T AT E411038 T1 ATE411038 T1 AT E411038T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- activator
- cancer treatment
- neutrophil cells
- reduce neutropenia
- Prior art date
Links
- 102000013674 S-100 Human genes 0.000 title abstract 2
- 108700021018 S100 Proteins 0.000 title abstract 2
- 210000000440 neutrophil Anatomy 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000004235 neutropenia Diseases 0.000 title 1
- 102100032442 Protein S100-A8 Human genes 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 102100029812 Protein S100-A12 Human genes 0.000 abstract 1
- 102100032420 Protein S100-A9 Human genes 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45802203P | 2003-03-28 | 2003-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE411038T1 true ATE411038T1 (de) | 2008-10-15 |
Family
ID=33098257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04723142T ATE411038T1 (de) | 2003-03-28 | 2004-03-25 | S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7632802B2 (de) |
| EP (1) | EP1608397B1 (de) |
| AT (1) | ATE411038T1 (de) |
| CA (1) | CA2520515C (de) |
| DE (1) | DE602004017148D1 (de) |
| WO (1) | WO2004084928A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553488B2 (en) * | 2002-07-05 | 2009-06-30 | UNIVERSITé LAVAL | Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions |
| EP1784216A4 (de) * | 2004-07-13 | 2009-06-03 | Univ Laval | S100 proteinhemmer zur behandlung von leukämie |
| CA2636788A1 (en) * | 2006-10-30 | 2008-05-08 | Genomix Co., Ltd. | Hmgb protein for use in promoting tissue regeneration |
| WO2009133943A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 生体内機能的細胞の高効率採取法 |
| JP5660889B2 (ja) * | 2008-04-30 | 2015-01-28 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
| CN102076351A (zh) * | 2008-04-30 | 2011-05-25 | 吉诺米克斯股份有限公司 | 损伤组织的功能性再生促进药物 |
| US8173598B2 (en) | 2008-08-29 | 2012-05-08 | The Board Of Trustees Of The University Of Illinois | Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway |
| KR20120135190A (ko) | 2009-10-28 | 2012-12-12 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제 |
| EP3358011B1 (de) | 2011-04-26 | 2020-03-04 | StemRIM Inc. | Peptide zur induktion der regenerierung von gewebe und verwendung davon |
| JP6253589B2 (ja) | 2012-10-25 | 2017-12-27 | 株式会社ジェノミックス | Ｈｍｇｂ１断片を利用した新規心筋梗塞の治療法 |
| DK2913059T3 (en) | 2012-10-25 | 2018-06-25 | Genomix Co Ltd | Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT |
| WO2016134463A1 (en) * | 2015-02-25 | 2016-09-01 | UNIVERSITé LAVAL | S1009a peptide for treating leukemias |
| AU2018213671B2 (en) | 2017-01-27 | 2024-06-06 | Osaka University | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure |
| EP3718561A4 (de) | 2017-12-01 | 2021-07-21 | Stemrim Inc. | Therapeutikum für entzündliche darmerkrankung |
| AU2018376452A1 (en) | 2017-12-01 | 2020-06-25 | Osaka University | Ectodermal mesenchymal stem cells and method for producing same |
| US20210024594A1 (en) | 2018-02-08 | 2021-01-28 | StemRIM Inc. | Therapeutic Agent for Psoriasis |
| US12304933B2 (en) | 2018-10-05 | 2025-05-20 | StemRIM Inc. | Disease treatment drug based on mesenchymal-stem-cell mobilization |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| FR2587707B1 (fr) | 1985-09-23 | 1988-01-08 | Compiegne Universite Technolog | Glycopeptide et toute composition le contenant, leur procede de preparation et leurs applications anticoagulantes |
| DE3789413T2 (de) | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5714585A (en) | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| EP0550506B1 (de) | 1990-09-05 | 2002-11-20 | The Heart Research Institute Limited | Chemotaktische faktoren |
| ATE206056T1 (de) | 1992-06-08 | 2001-10-15 | Takeda Chemical Industries Ltd | Therapeutisches agens für neutropenie |
| AU5420796A (en) | 1996-03-11 | 1997-10-01 | Human Genome Sciences, Inc. | Chemotactic cytokine ii |
| US5849528A (en) | 1997-08-21 | 1998-12-15 | Incyte Pharmaceuticals, Inc.. | Polynucleotides encoding a human S100 protein |
| DE19811047C1 (de) | 1998-03-13 | 1999-04-15 | Fraunhofer Ges Forschung | Metallhaltige Ribonukleotidpolypeptide |
| US6117989A (en) | 1998-03-26 | 2000-09-12 | Incyte Pharmaceuticals, Inc. | Human calcium-binding proteins |
| AU765719B2 (en) | 1998-10-06 | 2003-09-25 | Trustees Of Columbia University In The City Of New York, The | Extracellular novel rage binding protein (EN-RAGE) and uses thereof |
| EP1066834A3 (de) | 1999-07-08 | 2004-06-02 | Thomas Dr. Stief | Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens |
| DE10121254A1 (de) * | 2001-04-30 | 2002-11-07 | Switch Biotech Ag | MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind |
| US7553488B2 (en) | 2002-07-05 | 2009-06-30 | UNIVERSITé LAVAL | Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions |
| EP1784216A4 (de) | 2004-07-13 | 2009-06-03 | Univ Laval | S100 proteinhemmer zur behandlung von leukämie |
-
2004
- 2004-03-25 WO PCT/CA2004/000451 patent/WO2004084928A1/en not_active Ceased
- 2004-03-25 AT AT04723142T patent/ATE411038T1/de not_active IP Right Cessation
- 2004-03-25 CA CA2520515A patent/CA2520515C/en not_active Expired - Fee Related
- 2004-03-25 US US10/551,234 patent/US7632802B2/en not_active Expired - Fee Related
- 2004-03-25 EP EP04723142A patent/EP1608397B1/de not_active Expired - Lifetime
- 2004-03-25 DE DE602004017148T patent/DE602004017148D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004017148D1 (de) | 2008-11-27 |
| EP1608397A1 (de) | 2005-12-28 |
| US20060281674A1 (en) | 2006-12-14 |
| CA2520515A1 (en) | 2004-10-07 |
| WO2004084928A1 (en) | 2004-10-07 |
| US7632802B2 (en) | 2009-12-15 |
| EP1608397B1 (de) | 2008-10-15 |
| CA2520515C (en) | 2012-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004017148D1 (de) | S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung | |
| Alvarez et al. | Regulatory T cell phenotype and anti-osteoclastogenic function in experimental periodontitis | |
| ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
| ATE381336T1 (de) | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten | |
| ATE382053T1 (de) | System zur antikörperexpression und- synthese | |
| IS8432A (is) | Mótefni sem bindast viðtaka hvítfrumuboða-4 | |
| WO2003066072A3 (en) | Cell therapy using immunoregulatory t-cells | |
| van Leuven et al. | Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis | |
| Sonouchi et al. | Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2 | |
| CY1116107T1 (el) | Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων | |
| ATE455463T1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| EA201190080A1 (ru) | Стабильные формы гранулоцитарных колоний рекомбинантного человеческого альбумина, стимулирующие фактор гибридного белка | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| EP1603391A4 (de) | Verfahren zur verwendung von zusammensetzungen, umfassend hitzeschockproteine oder alpha-2-macroglobulin bei der behandlung von krebs und infektionskrankheiten | |
| WO2004073657A3 (en) | Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases | |
| EA200600424A1 (ru) | Применение полипептидов семейства купредоксинов при лечении рака | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| Mocellin et al. | Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment | |
| ATE494301T1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
| EP2083018A3 (de) | Zusammensetzungen und Verfahren mit Bezug zu STOP-1 | |
| EA200600936A1 (ru) | Способы регуляции фактора некроза опухоли альфа | |
| DE50210637D1 (de) | Verwendung von stimulierten mononuklearen zellen des peripheren blutes zur behandlung von krebserkrankungen | |
| Arai et al. | A solid tumor of donor cell-origin after allogeneic peripheral blood stem cell transplantation | |
| Grabarek et al. | Differences in expression of genes related to drug resistance and miRNAs regulating their expression in skin fibroblasts exposed to adalimumab and cyclosporine A | |
| WO2004089292A3 (en) | Immunomodulatory agents for treatment of inflammatory diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |